Latest California Healthline Stories
In this special episode of KFF Health News’ “What the Health?” host Julie Rovner interviews three health policy experts.
The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?
Research commissioned by the Centers for Medicare & Medicaid Services analyzed only staffing levels below what experts have previously called ideal. Patient advocates have been pushing for more staff to improve care.
In Bangladesh, smallpox eradication workers went to great lengths to vaccinate even one person, sometimes traveling by speedboat, crossing rickety bamboo bridges or leech-infested paddy fields. Episode 4 of the “Eradicating Smallpox” podcast is about what it takes to bring care directly to people where they are.
Teens share photos or videos of themselves with guns and stacks of cash, sometimes calling out rivals, on Facebook, Instagram, Snapchat, or TikTok. When posts go viral, fueled by “likes” and comments, the danger is hard to contain.
As chatter and images about guns and violence slip into the social media feeds of more teens, viral messages fueled by “likes” can lead to real-world conflict and loss.
The first Republican presidential debate of the 2024 cycle took place without front-runner Donald Trump — and with hardly a mention of health issues save for abortion. Meanwhile, in Florida, patients dropped from the Medicaid program are suing the state for not giving them enough notice or a way to contest their being dropped from the program. Margot Sanger-Katz of The New York Times, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Victoria Knight of Axios join KFF Health News’ Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
A federal appeals court issued a split decision on whether the abortion pill mifepristone should remain on the market — rejecting a lower court’s decision to effectively cancel the drug’s FDA approval in 2000, while ordering the rollback of more recent rules that made the drug easier to obtain. Nothing changes immediately, however, as the Supreme Court blocked the lower court’s ruling in the spring. It will be up to the high court to determine whether the pill remains available in the U.S. and under which conditions. Sarah Karlin-Smith of the Pink Sheet, Alice Miranda Ollstein of Politico, and Shefali Luthra of The 19th join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
The No Surprises Act has helped rein in out-of-network medical bills, but ground ambulances are a costly exception. Hear why this service can still hit patients with big bills and what to do if you get one.
In the early 1970s, public health workers buoyed by the motto “zero pox!” worked across India to achieve 100% vaccination against smallpox. This episode is about what happened when these zealous young people encountered hesitation.